Patents by Inventor Yi-Rang KIM
Yi-Rang KIM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240243279Abstract: The present invention provides a positive electrode active material precursor having a uniform particle size distribution and a method of preparing the same, and, specifically, provides a positive electrode active material precursor represented by Formula 1, wherein a percentage of fine powder with an average particle diameter (D50) of 1 ?m or less generated when the positive electrode active material precursor is rolled at 2.5 kgf/cm2 is less than 1%, and an aspect ratio is 0.93 or more, and a method of preparing the positive electrode active material precursor. [NixCOyM1zM2w](OH)2??[Formula 1] In Formula 1, 0.55?x<1, 0<y?0.5, 0<z?0.5, and 0?w?0.1, M1 includes at least one selected from the group consisting of Mn and Al, and M2 includes at least one selected from the group consisting of Zr, B, W, Mo, Cr, Nb, Mg, Hf, Ta, La, Ti, Sr, Ba, Ce, F, P, S, and Y.Type: ApplicationFiled: March 28, 2024Publication date: July 18, 2024Applicant: LG Chem, Ltd.Inventors: Seong Bae Kim, Yi Rang Lim, Kyoung Wan Park, Hyun Uk Kim, Hong Kyu Park, Chang Jun Moon, Eun Hee Kim
-
Publication number: 20240216384Abstract: The present invention relates to a composition for preventing or treating metabolic diseases, containing 10-ethoxy-8-(morpholinomethyl)-2,3,4,6-tetrahydrobenzo[h][1,6]naphthyridin-5(1H)-one, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a salt hydrate thereof as an active ingredient. Due to an adipocyte differentiation inhibitory effect, a fat accumulation inhibitory effect, an NAFLD inhibitory effect, and an NASH-induced fibrosis inhibitory effect of the composition, it is possible to prevent or treat metabolic diseases including nonalcoholic steatohepatitis (NASH), NASH-associated liver fibrosis, nonalcoholic fatty liver (NAFL), and NAFLD-associated liver fibrosis, fatty liver, and obesity.Type: ApplicationFiled: April 27, 2022Publication date: July 4, 2024Applicants: ONCOCROSS CO.,LTD., JEIL PHARMACEUTICAL CO.,LTDInventors: Yi Rang KIM, Sang Yun PARK, Ga Eul YANG
-
Publication number: 20240207236Abstract: The present invention relates to a use of (R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6] naphthyridine-5-yloxy]-ethyl}pyrrolidine-2-one for treating diabetes. According to the present invention, (R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6] naphthyridine-5-yloxy]-ethyl}pyrrolidine-2-one of the present invention alleviates clinical symptoms of diabetes, reduces blood sugar, reduces blood glucose concentrations and insulin-resistance and reduces liver and kidney damages in an animal model of insulin-resistant diabetes, and thus can be effectively used for preventing or treating diabetes, especially insulin-resistant diabetes.Type: ApplicationFiled: March 31, 2022Publication date: June 27, 2024Applicant: ONCOCROSS CO., LTD.Inventor: Yi Rang KIM
-
Publication number: 20240197695Abstract: The present disclosure relates to a use of (R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6] naphthyridin-5-yloxy]-ethyl}pyrrolidin-2-one in treating kidney disease. According to the present disclosure, (R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6] naphthyridin-5-yloxy]-ethyl}pyrrolidin-2-one of the present disclosure palliates clinical symptoms and alleviates renal failure and renal injury through reduction of blood glucose levels and insulin resistance in diabetic nephrosis animal models. Thus, the compound may be advantageously applied to a use for preventing or treating kidney diseases, especially diabetic renal diseases.Type: ApplicationFiled: March 31, 2022Publication date: June 20, 2024Applicant: ONCOCROSS CO.,LTDInventor: Yi Rang KIM
-
Publication number: 20240108611Abstract: The present invention relates to a composition for the treatment of metabolic diseases, containing torsemide and cromolyn. According to the present invention, if torsemide and cromolyn are used in combination, compared to when cromolyn alone is used, weight is reduced, insulin resistance is reduced and liver fat accumulation is remarkably reduced in a NASH animal model, and thus the present invention can be effectively used in the prevention or treatment of metabolic diseases including diabetes, obesity, insulin resistance and metabolic liver diseases.Type: ApplicationFiled: February 7, 2022Publication date: April 4, 2024Applicant: ONCOCROSS CO., LTD.Inventor: Yi-Rang KIM
-
Publication number: 20240062851Abstract: A method for diagnosing cancer of unknown primary site by using artificial intelligence is disclosed. A method for diagnosing cancer of unknown primary site by using artificial intelligence, according to one embodiment of the present invention, includes the steps of: generating gene expression pattern information of a sample collected from tissue in which metastatic cancer has occurred; removing gene expression pattern information derived from pre-learned tissue from the gene expression pattern information of the sample collected from the tissue in which the metastatic cancer has occurred; comparing the gene expression pattern information from which the gene expression pattern information derived from the tissue has been removed with pre-learned gene expression pattern information for each cancer type; and specifying a primary site of the sample collected from the tissue in which the metastatic cancer has occurred.Type: ApplicationFiled: September 22, 2022Publication date: February 22, 2024Inventors: Young Heun LEE, Yi Rang KIM, Ji Hoon KANG
-
Publication number: 20230402130Abstract: A method, a device, and a computer program for predicting the interaction between a compound and a protein are provided. A method for predicting the interaction between a compound and a protein, according to some embodiments of the present disclosure, may include: acquiring compound data for training, protein data for training, and training data including interaction scores; constructing a deep-learning model by using the acquired training data; and predicting the interaction between the given compound and protein by using the constructed deep-learning model. The interaction between the given compound and protein in an in vivo environment can be accurately predicted by training the deep-learning model, while excluding, from an amino acid sequence of the protein for training, amino acid sequences associated with a protein domain having a negative influence on the interaction.Type: ApplicationFiled: December 6, 2021Publication date: December 14, 2023Applicant: ONCOCROSS CO., LTD.Inventors: Jin Woo CHOI, Yi Rang KIM
-
Publication number: 20230301953Abstract: The present invention relates to a pharmaceutical composition comprising calcium pantothenate, or calcium pantothenate and dimenhydrinate as active ingredients for prevention and treatment of myopathy. According to the present disclosure, calcium pantothenate upregulates the expression of MHC, myogenin 4-EBP, and p70S6K to promote myoblast differentiation and myogenesis, thereby prolonging the duration of life in amyotrophic lateral sclerosis patients and promoting the growth of MSC in Duchenne muscular dystrophy mice. Such effects are synergistically increased upon combined treatment with dimenhydrinate. Thus, they can be advantageously used for preventing or treating myopathy.Type: ApplicationFiled: August 10, 2021Publication date: September 28, 2023Applicant: ONCOCROSS CO.,LTD.Inventor: Yi-Rang KIM
-
Publication number: 20230063188Abstract: Provided are a method, an apparatus, and a computer program for predicting interaction between a compound and a protein. A method for predicting interaction between a compound and a protein according to some embodiments of the present disclosure may comprises the steps of: acquiring learning data composed of compound data for learning, protein data for learning, and interaction scores; constructing a deep-learning model by using the acquired learning data; and predicting interaction of a given compound and protein through the constructed deep-learning model. Through the learning of the deep-learning mode with the exclusion of amino acid sequences associated with protein domains having a negative influence on interactions from amino acid sequences of proteins for learning, the interaction between a given compound and protein in the in vivo environment can be accurately predicted.Type: ApplicationFiled: December 14, 2020Publication date: March 2, 2023Inventors: Jin Woo CHOI, Yi Rang KIM
-
Publication number: 20230042132Abstract: A disease prediction method, apparatus, and computer program are provided. A disease prediction method according to several embodiments of the present disclosure can comprise the steps of: constructing a disease prediction model by learning learning data including ribosome data and disease information for learning, acquiring test ribosome data of an examinee; and predicting disease information about the examinee form the test ribosome data by using the disease prediction model. The disease prediction model can accurately predict disease information about the examinee by detecting and learning the characteristics of ribosome data, which vary according to disease information.Type: ApplicationFiled: December 14, 2020Publication date: February 9, 2023Inventors: Jin Woo CHOI, Yi Rang KIM
-
Publication number: 20220273642Abstract: The present disclosure relates to an effect of inhibiting cancer metastasis by treatment of chlorphenesin and hydroxychloroquine alone or in combination. Chlorphenesin or hydroxychloroquine has the effect of inhibiting the metastasis and invasion of cancer cells. In particular, since it was identified that a combination thereof has a synergistic action, it is possible to effectively prevent or treat cancer metastasis by administering chlorphenesin and hydroxychloroquine respectively or in combination thereof.Type: ApplicationFiled: May 11, 2022Publication date: September 1, 2022Applicant: ONCOCROSS CO., LTD.Inventors: Yi-Rang Kim, Sang Yun Park, Ga Eul Yang, Seung Jun Lee
-
Publication number: 20220265663Abstract: The present invention relates to a pharmaceutical composition for prevention or treatment of a muscular disease, the composition comprising dimenhydrinate, harmol and/or calcium pantothenate as active ingredients. Application of dimenhydrinate, harmol, and calcium pantothenate individually has an effect of promoting myoblast proliferation and differentiation. In particular, the combination thereof has the effect of synergistically increasing the effect of promoting myoblast proliferation and differentiation. Thus, dimenhydrinate, harmol and/or calcium pantothenate may be usefully used alone or in combination for the prevention or treatment of muscular diseases, in particular sarcopenia.Type: ApplicationFiled: May 13, 2022Publication date: August 25, 2022Inventors: Yi-Rang KIM, Jin-Woo CHOI
-
Patent number: 11364237Abstract: The present invention relates to an anticancer and metastasis inhibiting effect by treatment with chlorphenesin, chloroquine, and chloropyrazine alone or in combination. Chlorphenesin, chloroquine, or chloropyrazine show the effect of killing cancer cells and inhibiting proliferation, and metastasis of cancer cells and particularly, a combination thereof is identified to have synergism. Cancer can be effectively prevented or treated by administering chlorphenesin, chloroquine, and chloropyrazine alone or in combination thereof.Type: GrantFiled: February 6, 2018Date of Patent: June 21, 2022Assignee: ONCOCROSS CO., LTD.Inventor: Yi-Rang Kim
-
Patent number: 11364244Abstract: The present invention relates to a pharmaceutical composition for prevention or treatment of a muscular disease, the composition comprising dimenhydrinate, harmol and/or calcium pantothenate as active ingredients. Application of dimenhydrinate, harmol, and calcium pantothenate individually has an effect of promoting myoblast proliferation and differentiation. In particular, the combination thereof has the effect of synergistically increasing the effect of promoting myoblast proliferation and differentiation. Thus, dimenhydrinate, harmol and/or calcium pantothenate may be usefully used alone or in combination for the prevention or treatment of muscular diseases, in particular sarcopenia.Type: GrantFiled: April 17, 2019Date of Patent: June 21, 2022Assignee: ONCOCROSS CO., LTD.Inventors: Yi-Rang Kim, Jin-Woo Choi
-
Publication number: 20200246343Abstract: The present invention relates to a pharmaceutical composition for prevention or treatment of a muscular disease, the composition comprising dimenhydrinate, harmol and/or calcium pantothenate as active ingredients. Application of dimenhydrinate, harmol, and calcium pantothenate individually has an effect of promoting myoblast proliferation and differentiation. In particular, the combination thereof has the effect of synergistically increasing the effect of promoting myoblast proliferation and differentiation. Thus, dimenhydrinate, harmol and/or calcium pantothenate may be usefully used alone or in combination for the prevention or treatment of muscular diseases, in particular sarcopenia.Type: ApplicationFiled: April 17, 2019Publication date: August 6, 2020Applicant: ONCOCROSS CO., LTD.Inventors: Yi-Rang KIM, Jin-Woo CHOI
-
Publication number: 20190374538Abstract: The present invention relates to an anticancer and metastasis inhibiting effect by treatment with chlorphenesin, chloroquine, and chloropyrazine alone or in combination. Chlorphenesin, chloroquine, or chloropyrazine show the effect of killing cancer cells and inhibiting proliferation, and metastasis of cancer cells and particularly, a combination thereof is identified to have synergism. Cancer can be effectively prevented or treated by administering chlorphenesin, chloroquine, and chloropyrazine alone or in combination thereof.Type: ApplicationFiled: February 6, 2018Publication date: December 12, 2019Applicant: ONCOCROSS CO., LTD.Inventor: Yi-Rang KIM